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Zwitterionic 7-methoxyimino cephalosporins (cefpirome, cefepime, cefclidin,
DQ2556, FK.O37 and SCE2787) possess a variable substitution at C3 which contains
a quaternary nitrogen. These cephalosporins display low affinities for Class I
/J-lactamase and rapid penetration through the outer membrane of Gram-negative
bacilli, so that an increased number of periplasmic /Mactam molecules interact with
PBP's per unit of time. As a consequence, the new zitterionic compounds remain active
against some, but not all, ceftazidime-resistant Enterobacteriaceae producing high
levels of Class I /Mactamase or Bush type 2b /J-lactamases. Antipseudomonas activities
are generally similar to that of ceftazidime except that cefclidin is more active. The new
zwitterionic compounds, especially cefpirome and FK037, express greater
antistaphylococcal potency than does ceftazidime. A variety of animal models
including meningitis and endocarditis have confirmed the potential of these
compounds in-vivo. On the basis of structural and antibacterial characteristics, the
expression 'forth generation' is acceptable to describe the zwitterionic 7-methoxyimino
cephalosporins.
Introduction
During recent years, cephalosporins which possess an aminothiazolyl-oxyimino moiety,
such as cefotaxime, ceftriaxone and ceftazidime (the 'third generation' cephalosporins),
have been used extensively. The emergence of bacterial strains which are resistant to these
compounds has, however, caused some concern about their use in certain circumstances.
Resistance in Gram-negative bacteria is principally associated with the production of
hydrolysing enzymes, particularly Class 1 chromosomal /?-lactamases and plasmid
encoded, extended spectrum /Mactamases. Many bacteria which synthesise these enzymes
also possess an impermeable outer membrane. A new class of 7-methoxyimino
cephalosporins, which are zwitterions has been developed in order to circumvent these
potential mechanisms of resistance. This new class includes cefpirome, cefepime, cefclidin
(previously E1040), DQ2556 and FK037 (Figure 1) (Jones et al., 1990, 1991 b; Pucci et ai,
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Table I. Factors influential in /?-lactam activity against a /?-lactamase hyperproducer E. cloacae
strain
Antibiotic
Cephaloridine
Cefotaxime
Cefpirome
Cefepime
Outer
membrane
permeability
parameter
P (nm/s)
960
5.6
37
29
/NLactamase
Km (/im)
140
0.2
140
180
kinetic constants
u
r
 max(pmol/mg/s)
1650000
55
250
216
Antibiotic
concentration
in periplasm at
the MIC (nM)
>2180
13
200
250
Adapted from (Bellido el al., 1991).
1991). Other products, such as cefozoprane (SCE2787), belong to the same class but the
available data are preliminary.
Chemical structure and mode of action
The five new compounds shown in the Figure resemble third generation cephalosporins
in possessing a cephem ring with an oxyimino moiety in the /^-orientation at the carbon
7 position. All the compounds possess an aminothiazolyl group at C7 as in the third
generation cephalosporins, apart from cefclidin with the closely related aminothiadiazolyl
system. The main structural feature of the new compounds is a variable substitution at
C3 which contains a quaternary nitrogen. This group is intrinsically positively charged
in both acidic and alkaline conditions, and with the negatively charged carboxyl group
makes these molecules zwitterions at the pH range encountered in vivo.
Several factors influence the activity of a /Mactam molecule against-Gram negative
bacteria: the permeability of the outer bacterial membrane; the affinity for /Mactamase,
which can be estimated by determining the Km; the activity of the /Mactamase, as described
by Vmu', and the affinity for target proteins, i.e. the penicillin binding proteins (PBP). A
new class of zwitterionic 7-methoxyimino cephalosporins have recently been developed
which are active against Enterobacteriaceae that are resistant to third generation
cephalosporins. The enhanced activities of cefpirome, cefepime and cefclidin against
Class 1 /Mactamase hyper-producers are associated with low affinities (i.e. relatively high
A",,, values) for these enzymes (Table I) (Kobayashi et al., 1986; Phelps et al., 1986; Hiraoka
et al., 1988; Nikaido, Liu & Rosenberg, 1990; Bellido, Pechere & Hancock, 1991).
DQ2556 appears to differ slightly in this respect since its Km values for /Mactamases
produced by Citrobacter freundii and Enterobacter cloacae are only two or three-fold
higher than thoseofceftazidime(Fujimotoe/a/., 1990). In addition, the new zwitterionic
7-methoxyimino cephalosporins are highly resistant to hydrolysis by Class 1 /Mactamase,
even though the ^ values are somewhat higher than those observed with third
generation cephalosporins (Table I).
Overall, the new zwitterionic cephalosporins appear more stable to Class 1
/Mactamases as a result of the low affinities of these antibiotics for the enzymes and
the reduced activities of the enzymes. Although the Km values are similar for
cephaloridin and the newer zwitterionic compounds, the much lower V^ values
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associated with the latter cephalosporins account for their superior ability to resist
hydrolysis. Other studies have shown that the zwitterionic 7-methoxyimino
cephalosporins are susceptible to hydrolysis by /Mactamases derived from Bacteroides
fragilis, or by the oxyimino cephalosporinases from Stenotrophomonas maltophila,
Proteus vulgaris and Burkholderia (Pseudomonas) cepacia (Kobayashi et al., 1986;
Fujimoto et al., 1990).
Studies on the permeability of bacterial outer membranes to the new zwitterionic
cephalosporins have provided some interesting information. Results from proteolipo-
some assays initially indicated that cefpirome, cefepime and cefclidin penetrate
Escherichia coli and E. cloacae several times faster than cefotaxime and ceftazidime
(Nikaido et al., 1990). A novel HPLC-based method expanded this observation to intact
cells (Bellido e/a/., 1991). These studies demonstrated that, although the new zwitterionic
cephalosporins are slightly larger molecules than the third generation cephalosporins,
cefpirome and cefepime penetrated the outer membrane of E. cloacae between five and
seven times more rapidly than cefotaxime and ceftriaxone. This is probably due to the
presence of the positive moiety in these antibiotics and the selectivity of the OmpF
porins for cations as compared with anions (Benz, Schmid & Hancock, 1985).
Experiments involving an OmpF-deficient mutant strain have shown that a significant
proportion of DQ2556 enters E. coli via the OmpF porin (Fujimoto et al., 1990; Nikaido
et al., 1990).
Cephaloridine (a first generation cephalosporin) is also a dipolar ionic molecule with
a quaternary nitrogen at the C3 position with no net charge (Figure). It penetrates
bacterial membranes even more rapidly than the new zwitterionic cephalosporins (Bellido
et al., 1991). There are two possible reasons for this speed of penetration: the shape and
small size of the cephaloridine molecule and the absence of a methoxyimino moiety at
the C7 position, which is a structural feature that decreases the rate of penetration of
monoanionic cephalosporins (Yoshimura & Nikaido, 1985). By contrast, ceftazidime,
which has a positive charge at the C3 position but a net negative charge, penetrates the
outer membrane much more slowly. This is probably because this anionic compound is
retarded by the interior, negative, Donnan potential of the bacterium (Sen, Halleman &
Nikaido, 1988).
The rapid penetration through bacterial membranes and weak affinity for
/?-lactamases of new zwitterionic cephalosporins mean that an increased number of
periplasmic /Mactam molecules are available to interact with their target proteins per unit
time. The targets for the /?-lactams in Gram-negative bacteria are PBPs located in the
cytoplasmic membrane. Based on estimates of the minimal periplasmic antibiotic
concentration required to inhibit cell wall synthesis, cefpirome and cefepime have a
10-20-fold lower affinity for E. cloacae PBPs than cefotaxime and ceftriaxone
(Bellido et al., 1991). The major target site for the zwitterionic 7-methoxyimino
cephalosporins in E. coli is PBP3. The IC50S for the five compounds have been calculated
at ^0.5 mg/L; moderate affinities were also calculated for PBP1 (Watanabe et al., 1988;
Fujimoto et al., 1990; Pucci et al., 1991; Piddock, Traynor & Griggs, 1992; Tanaka,
Otsuki & Nishino, 1992). In addition, cefepime was shown to have a 20-fold lower ICso
value for E. coli PBP2 compared with corresponding values for cefpirome and cefclidin
(Pucci et al., 1991).
Cefpirome, cefepime and cefclidin induced the production of filaments in E. coli
exposed to concentrations close to the MIC (Watanabe et al., 1988; Pucci et al., 1991).
Cefepime also generated bleb formation along the filaments when present at a
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concentration 10-fold higher than the MIC (Watanabe et al., 1988; Pucci et al., 1991).
With respect to Pseudomonas aeruginosa, the affinities of cefpirome, cefepime, cefclidin
and DQ2556 were high, moderate and poor for PBP3, PBP1 and PBP2, respectively
(Watanabe et al., 1988; Fujimoto et al., 1990; Pucci et al., 1991). Cefpirome had the
highest affinity for PBP2, PBP1 and PBB3 isolated from methicillin-susceptible
Staphylococcus aureus (MSSA); DQ2556 exhibited the next highest affinity (Fujimoto
et al., 1990). Cefpirome and FK037 bound PBP1 and PBP2 from methicillin-resistant S.
aureus (MRSA) and showed limited affinities (FK037 more than cefpirome) for PBP2a,
which correlates with their antibacterial activities (Piacentini et al., 1992; Piddock et al.,
1992). However, PBP2a was not saturated despite exposure to 64mg/L of cefpirome
(Piddock et al., 1992).
In-vitro antibacterial activities
Gram-negative organisms
The effectiveness of /Mactams against Enterobacteriacea depends on the type of
/Mactamase produced by the target strain. No clear benefits, as compared with
ceftazidime, have been demonstrated in vitro for the zwitterionic 7-methoxyimino
cephalosporins with respect to strains which do not produce Class 1 chromosomally
mediated /Mactamase or extended spectrum /Mactamases, such as E. coli, indole-negative
Proteus spp., Klebsiella spp. or Salmonella spp. However, cefepime and FK.O37 were active
(MIC90 8 and 4 mg/L, respectively) against a collection of ceftazidime-resistant Klebsiella
pneumoniae (MIC90 > 64 mg/L). Such data indicate the greater activity of these antibiotics
compared with ceftazidime, but also suggest that the newer compounds are subject to
some degree of hydrolysis. Other species, including Enterobacter spp. indole-positive
Proteus spp., Providencia spp., Morganella spp., Citrobacter spp. and Serratia
spp. produce low levels of Class 1 /Mactamase, which may be significantly increased by
induction or mutational derepression. These high /Mactamase producers are protected
against the third generation cephalosporins but are susceptible to the zwitterionic
7-methoxyimino cephalosporins (MIC9o<8 mg/L). The increased antibacterial potency
of the latter compounds is illustrated for E. cloacae in Table II. In addition, cefpirome
generates significant /Mactamase induction less frequently than ceftazidime in E. cloacae
(Reeves, Bywater & Holt, 1993).
A proportion of Enterobacteriacea which produce high levels of Class 1 /Mactamase,
however, are resistant to the zwitterionic 7-methoxyimino cephalosporins. Cefepime can
select derepressed mutants in vitro and in vivo (Piddock & Griggs, 1991; Pechere &
Vladoianu, 1992), but to a lesser extent than ceftazidime. Recent multicentre studies have
indicated that 6% and 10% of E. cloacae clinical isolates in USA and Europe respectively,
are resistant to cefpirome; approximately 30% of strains in both areas were found to be
ceftazidime resistant (Jones et al., 19916; Verbist & International Study Group, 1993).
The newer compounds have not yet been compared in the same study. Overall, cefpirome,
cefepime and cefclidin seem to display similar activities against Enterobacteriacea which
produce Class 1 /Mactamase, while FK037 and DQ2556 appear to be slightly less active
than cefpirome or cefepime (Fujimoto etal., 1990; Jones et al., 1991 b;Tanaka et al., 1992;
Fu et al., 1993; Washington et al., 1993).
The zwitterionic 7-methoxyimino cephalosporins are active against strains which
synthesise the Bush type 2b /Mactamases (TEM-1, TEM-2, SHV-1), but, overall,
resistance to cefepime, cefpirome, cefclidin and FKO37 is enhanced in strains which
Table II. MIG^s (mg/L) of ceftazidime and five C3-substituted methoxyimino cephalosporins against E. cloacae
Number of
strains tested
127
236
105
36
27
20
20
322
46
60
Ceftazidime
64
>16
50
2
1.56
>16
128
>16
64
100
Cefpirome
2
8
6.25
0.5
0.2
0.5
1
Cefep:
0.5
0.1
4
8
DQ-2556 FK-037 Cefclidin Reference
25
0.39
16
(Reeves et al., 1993)
(Jones et al., 1991)
(Fujimoto et al., 1990)
(King et al., 1990)
0.2 (Tanaka et al., 1992)
1 (Jones et al., 1991)
(Fnetal., 1993)
(Washington et al., 1993)
(Neu et al., 1993)
3.13 (Watanabe et al., 1988)
Table HI. MIG»s (mg/L) of ceftazidime and five C3-substituted methoxyimino cephalosporins against P. aeruginosa
Number of
strains tested Ceftazidime Cefpirome Cefepime DQ-2556 FK-037 Cefclidin Reference
(King el al., 1990)
(Verbist & International
Study Group, 1993)
0.78 (Tanaka et al., 1992)
32 (Fu et al., 1993)
(Fujimoto et al., 1990)
(Fujimoto et al., 1990)
6.25 (Watanabe et al., 1992)
1 (Jones et al., 1991)
32 (Washington et al., 1993)
6.25 (Watanabe et al., 1992)
ft
a.
35
1012
43
61
101"
26*
334
30
651
334
4
£32
3.13
64
6.25
100
50
4
>16
50
8
£32
6.25
32
12.5
100
100
8
100
8
3.13
16
25
16
25
12
25
> 100
"Ceftazidime susceptible isolates.
'Ceftazidime resistant isolates.
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produce extended spectrum /Mactamases; MIC<8 mg/L have been recorded in most
cases, i.e. lower than those of ceftazidime (Jacoby & Can-eras, 1990; Jones et al., 1991a;
Neu, Chin & Huang, 1993). MICs of the newer compounds for clinical isolates are higher
than those determined with corresponding wild type strains, which suggest some degree
of hydrolysis. More active enzymes, such as TEM-9, SHV-2, SHV-3 or SHV-4, exist,
however, and these do render bacteria resistant to the zwitterionic 7-methoxyimino
cephalosporins (Jacoby & Carreras, 1990).
Cefpirome is slightly less active than ceftazidime against P. aeurginosa (Table III).
Multicentre studies have demonstrated that the proportion of isolates resistant to
ceftazidime and cefpirome in Europe was 24% and 31%, respectively; corresponding data
in USA were 10% and 18%, respectively (Jones et al., 1991; Verbist& International Study
Group, 1993). In a study of a collection of P. aeruginosa with well characterised resistance
mechanisms (non /Mactamase-mediated, production of Class 1 /Mactamase, or
plasmid-mediated /Mactamases) the MICs of cefpirome and ceftazidime were similar
(Gargalianos et al., 1988). Transconjugant studies demonstrated that LCR-1 and PSE-2
enzymes protected P. aeruginosa against cefpirome, but PSE-1, PSE-3, PSE-4, TEM-2
and OXA-6 enzymes did not (Gargalianos et al., 1988). An OXA-1-type penicillinase,
which hydrolysed cefclidin, was detected in a resistant P. aeruginosa strain (Watanabe,
Hiruma & Katsu, 1992). Most ceftazidime-resistant strains of P. aeruginosa examined in
one study were resistant to cefepine and cefpirome, but only 4% were resistant to cefclidin
(Watanabe et al., 1992). Cefclidin is the most active anti-/\ aeruginosa compound listed
in Table III, followed by cefepime, cefpirome, DQ2556 and FK037. A mutational OmpD
deficiency in isogenic P. aeruginosa strains did not affect the MICs of cefepime and
cefpirome (J. C. Pechere, unpublished observations).
Tobramycin acted synergistically with cefpirome, cefepime, cefclidin and ceftazidime
against 22-30% of P. aeruginosa isolates (Chin & Neu, 1989). A majority of Burkholderia
cepacia isolates should be considered as being resistant (MIC > 8 mg/L) to the zwitterionic
7-methoxyimino cephalosporins (and to ceftazidime), despite the existence of some
susceptible strains (Watanabe et al., 1988; Fujimoto et al., 1990; Fu et al., 1993). Most
S. maltophilia isolates are also resistant to the new compounds but several isolates are
susceptible to ceftazidime (Watanabe et al., 1988; Fujimoto et al., 1990; Jones et al.,
1991a; Fu et al., 1993; Reeves et al., 1993; Verbist & International Study Group, 1993;
Washington et al., 1993). Ceftazidime and the zwitterionic 7-methoxyimino
cephalosporins are equally active against Acinetobacter spp. (Watanabe et al., 1988;
Fujimoto et al., 1990; Jones et al., 1991a, b; Tanaka et al, 1992; Fu et al., 1993;
Washington et al., 1993).
In general, Haemophilus influenzae isolates are equally susceptible to all of these
molecules even when the bacteria produce /Mactamase (Watanabe et al., 1988; Fujimoto
etal., 1990; Tanaka et al., 1992; Fuel al., 1993; Reeves et al., 1993). 0-lactamase-negative
strains which were less susceptible to cefuroxime, however, were also less susceptible to
cefepime and cefpirome (James et al., 1992). Moraxella catarrhalis is susceptible to the
new zwitterionic 7-methoxyimino cephalosporins, but ceftazidime is more active against
this species (Tanaka et al., 1992; Fu et al., 1993; Washington et al., 1993).
Gram-positive organisms
The zwitterionic 7-methoxyimino cephalosporins possess interesting anti-staphylococcal
activities (Rolston & Bodey, 1986; Chin et al., 1991; Fuel al., 1993). According to MIG»
Table IV. MI&oS (mg/L) of ceftazidime and five C3-substituted methoxyimino cephalosporins against S. aureus
Phenotype
Methicillin-
susceptible
Methicillin-
resistant
Number of
strains tested
1035
186
43
36
21
121
31
576
90
51
23
36
91
47
41
Ceftazidime
16
0.5
50
16
8
25
8
8
16
25
128
> 100
>100
128
>64
Cefpirome
1
1
6.25
4
0.5
1.56
1
32
50
100
16
Cefepime
50
4
1
2
4
>100
64
>64
DQ-2556
6.25
1.56
50
50
FK-037
2
1
2
16
32
Cefclidin
12.5
8
12.5
>100
Reference
(Verbist & International
Study Group, 1993)
(Reeves et al., 1993)
(Tanaka et al., 1992)
(Fu et al., 1993)
(Jones et al., 1991)
(Fujimoto et al., 1990)
(King et al., 1990)
(Washington et al., 1993)
(Neu et al., 1993)
(Watanabe et al., 1988)
(Reeves et al., 1993)
(Tanaka et al., 1992)
(Fujimoto et al., 1990)
(Fu et al., 1993)
(Neu et al., 1993)
p
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values, they are more active than ceftazidime against S. aureus (Table IV) and
coagulase-negative staphylococci. Although the results of direct comparative studies
are not available, the activity of zwitterionic 7-methoxyimino cephalosporins against
methicillin-susceptible isolates is probably similar to that of cephalothin (the most potent
anti-staphylococcal cephalosporin). MIC90 of 2, 8 and 16 mg/L have been obtained for
cefpirome, cefepime and El040, respectively, against MSSA and methicillin-susceptible
coagulase-negative staphylococci (Rolston & Bodey, 1986; Chin et al., 1991). Some
MRSA are susceptible to the new zwitterionic antibiotics: 30% of MRSA strains in a USA
study had MICs of cefpirome <8mg/L (Jones et al., 1991ft). By comparison with
cefpirome, FK037 selected fewer highly resistant mutant strains of methicillin-resistant
staphylococci, showed a higher affinity for PBP 2a, and had lower MICs (Watanabe et al.,
1992). Because of the relative unreliability of MICs of methicillin-resistant staphylococci,
the practical value of these findings remain to be determined by appropriate clinical
studies.
Enterococcus faecalis and Enterococcus faecium are resistant to cephalosporins. It is
possible that the wide usage of these antibiotics accounts for the recent increases in the
number of enterococci observed in many hospitals. Some of the zwitterionic
7-methoxyimino cephalosporins may differ in this respect since cefpirome, FKO37,
cefepime and DQ2556 (but not cefclidin) exhibit limited activity against some E. faecalis
strains (Arai & Hayasi, 1990; Fujimoto et al., 1990; Jones et al., 1991ft; Tanaka et al.,
1992; Fu et al., 1993; Verbist & International Study Group, 1993; Washington et al.,
1993). The MICs of these antibiotics are relatively high and the practical value of these
observations when treating E. faecalis infections is probably limited. It is hoped, however,
that the use of the newer cephalosporins will be associated with fewer enterococcal
super-infections. E. faecium must be considered to be totally resistant to this class of
antibiotics.
The zwitterionic 7-methoxyimino cephalosporins are very active against most
Streptococcus spp., including against those alpha-haemolytic streptococci which cause
endocarditis (Wilcox et al., 1993). Streptococcuspneumoniae is also very susceptible, but
limited data suggest that increasing penicillin-resistance is associated with increasing
MICs of the new zwitterionic 7-methoxyimino cephalosporins (Spangler, Jacobs &
Appelbaum, 1994). The limited activity of these agents against Listeria monocytogenes,
another species which is generally resistant to older cephalosporins, probably lacks
clinical significance.
Strict anaerobes
Among anaerobic bacteria, B. fragilis has generally been found to be resistant to the
zwitterionic 7-methoxyimino cephalosporins, but the combination of cefpirome with
tazobactam enhanced the antibactericidal activity of the former (Watanabe et al., 1988;
Fujimoto et al., 1990; Jones et al., 1990; Kato et al., 1993; Neu et al., 1993). MIQoS of
cefpirome and FK037 < 1 mg/L have been determined for Clostridium perfringens,
Peptostreptococcus anaerobius and Peptostreptococcus asacharolyticus, Porphyromonas
gingivalis, Mobiluncus spp. and Gardnerella vaginalis (King, Boothman & Phillips, 1990;
Limbert et al., 1992; Kato et al., 1993).
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Table V. Penetration of antimicrobial agents into cerebrospinal fluid
(CSF)'
Antibiotic Percentage of serum concentration in CSF
Cefpirome 22
Cefepime 20
Ampicillin 12
Cefuroxime 9
Ceftriaxone 6
Cefoperazone 6
Cefotaxime 4
Penicillin 3
Cefamandole 2
Cephalothin 1
•Modified from Tauber el al. (1985).
Animal model studies
A number of studies have evaluated the in-vivo efficacy of new zwitterionic
cephalosporins. Most of these have studied the efficacy of cefpirome or cefepime. Limited
animal model data involving cefclidin, DQ2556 and FK037 have been published.
Meningitis
The penetration of C3 cephalosporins into cerebrospinal fluid (CSF) is good relative to
other /J-lactams. Cefpirome and cefepime treatment resulted in the highest percentage of
serum concentration of antibiotic in CSF in rabbits (Tauber et al., 1985, Table V). High
CSF concentrations of an antimicrobial agent relative to the MIC, and especially to the
MBC, of a microorganism are necessary for optimal efficacy in the treatment of
meningitis. The concentration in the CSF of an antimicrobial agent should be at least
10-30-fold higher than the MBC to achieve maximum activity (Tauber et al., 1985). As
a result of their excellent penetration into the CSF, the new zwitterionic cephalosporins
may represent a therapeutic advantage over other cephalosporins for the treatment of
central nervous system infections.
Cefpirome was as effective as cefotaxime in the treatment of 5. pneumoniae
experimental meningitis (Tauber et al., 1985). It was also highly effective therapy for
experimental meningitis caused by H. influenzae or E. coli (Jafari et al., 1991). Based on
the potent in-vitro activity of the zwitterionic cephalosporins and the results of animal
model studies, these drugs should be effective therapy for community-acquired meningitis
(except for infections caused by L. monocytogenes) and for hospital-acquired meningitis
due to susceptible strains of Enterobacteriacea. Additional studies are necessary to clarify
the role of new zwitterionic cephalosporins for the therapy of pseudomonal meningitis.
Infective endocarditis
Cephalosporins have been studied extensively for the treatment of experimental
endocarditis caused by staphylococci. First generation cephalosporins are considered to
be approximately equivalent in efficacy to nafcillin or oxacillin in vitro against MSSA and
in the therapy of experimental endocarditis caused by MSSA. Third generation
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Table VI. Results of 0-lactam treatment of 5. aureusendocarditis in rabbits (Steckelberg et al., 1993)
Treatment
number with sterile
number surviving/ vegetations/number
number treated number surviving
Logiocfu of
staphylococci/g of
vegetation
(mean±s.D.)
Rank
performance
In-vivo In-vitro'
None
Ceftizoxime
Cefotaxime
Ceftriaxone
Cefoperazone
Cefuroxime
Cefazolin
Cefpirome
Ceftazidime
Nafcillin
15/15
12/12
15/17
14/17
16/18
15/15
16/17
9/12
14/15
0/9
0/15
1/12
1/15
1/14
0/16
0/15
3/16
2/9
2/14
9.8±2.2
7.2±2.9*
6.7±3.7r
5.8±3.Or
4.9±3.3'
4.9 ±3.5'
4.0±2.6M
3.6 ±2.3*'
3.3 + 3.0"
2.3 ±1.6*^
9
8
7
6
5
4
3
2
1
8
6
7
5
4
2
3
9
1
'Based on the MIC with an inoculum of 105 cfu/mL.
for ceftizoxime compared with cefazolin, cefpirome, ceftazidime or nafcillin.
for cefotaxime or ceftriaxone compared with cefpirome, ceftazidime or nafcillin.
'P<, 0.05 for cefoperazone, cefuroxime or cefazolin compared with nafcillin.
cephalosporins are less active than cefazolin or nafcillin in vitro against MSSA (Donowitz
& Mandel, 1990) but animal model studies have suggested that this activity may not
correlate well with in-vivo efficacy (Baker & Fass, 1984; McColm, Ryan & Acred, 1984).
The efficacies of cefpirome, nafcillin and other cephalosporins for the treatment of
MSSA experimental endocarditis were compared in rabbits (Table VI) (Steckelberg et al.,
1993). Cefpirome, ceftazidime, and nafcillin were equivalent in efficacy and were
significantly more effective (/"<0.05) than cefuroxime, cefoperazone, ceftriaxone,
cefotaxime, or ceftizoxime. There was no significant difference between the outcome of
therapy with cefpirome or cefazolin. Previous studies have emphasised the discrepancy
between the in-vitro and in-vivo activity of ceftazidime against MSSA (Baker & Fuss,
1984; McColm & Ryan, 1985). McColm & Ryan (1985) suggested that this discrepancy
may be due to the good penetration of ceftazidime into cardiac vegetations. Lamb et al.
(1993) compared the efficacy of cefepime therapy of MSSA experimental endocarditis
with that of cefpirome, ceftazidime, vancomycin, and imipenem. Cefpirome was more
active than cefepime at comparable dosages. Cefpirome and vancomycin were equivalent
in efficacy and both were more effective than imipenem. Cefepime and ceftazidime
exhibited similar efficacy. The results of these studies suggest that semisynthetic penicillins
or first generation cephalosporins remain the /Mactams of choice for the treatment of
serious infection caused by MSSA. Although ceftazidime has been effective in therapy
of MSSA experimental endocarditis, we believe that, because of its high MIC90 value, this
drug should not be used preferentially for the treatment of MSSA infection.
Among the new zwitterionic cephalosporins, cefpirome was active in vivo in a mouse
thigh model of MRSA experimental infection (Eng et al., 1989). Cefpirome therapy was
superior to that of cephalothin and was similar in efficacy to vancomycin. In our
laboratory, cefpirome and cefazolin were significantly more effective (P < 0.05) than no
treatment of MRSA experimental endocarditis but these agents were significantly less
effective (Z'<0.05) than vancomycin (Tallan et al, 1989).
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Other animal model studies
Cefpirome was effective therapy for disseminated P. aeruginosa infection in leucopenic
mice (Valdes et al., 1990a). The addition of gentamicin or rifampin or of both antibiotics
did not significantly improve survival as compared to that resulting from monotherapy
with cefpirome. Additional animal model studies are necessary to clarify the role of new
zwitterionic cephalosporins combined with other antimicrobial agents to prevent the
emergence of resistance during therapy of Pseudomonas infection.
Klesel et al. (1984) reported that cefpirome was superior to cefotaxime, ceftazidime,
cefuroxime or cefoperazone in the therapy of experimental enterococcal infection. In a
separate study, cefpirome was more effective than ceftazidime in protecting mice with
systemic mixed infection caused by E. faecalis and E. coli (Arai & Hayashi, 1990).
Cefpirome was slightly more effective than therapy with ampicillin. However, the strain
of E. coli used in the mixed infection was resistant to ampicillin in vitro.
Conclusion
Many investigators have used the term 'fourth generation' cephalosporins to describe
the new zwitterionic cephalosporins (Neu, 1993; Sader & Jones, 1993). How valid is the
use of this term? As shown in this review, this novel class of cephalosporins shares
common structural features, a low affinity for class I /?-lactamases, a rapid penetration
through the outer membrane, and an extended antibacterial spectrum towards
Enterobacteriaceae and some Gram-positive cocci. On this basis, and where the
classification of cephalosporins into 'generations' seems acceptable the expression
'fourth generation' is appropriate for describing the zwitterionic 7-methoxyimino
cephalosporins, especially if the on-going clinical studies confirm the promising in-vitro
and animal data.
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